The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,972,410 | -7,171,529 |
| Depreciation and amortization | 5,429 | 10,857 |
| Stockbased compensation | 113,754 | 255,363 |
| Foreign currency loss (gain) | -5,691 | -80,927 |
| Prepaid expenses and other current and noncurrent assets | -169,996 | -347,749 |
| Accounts payable | -554,020 | -161,605 |
| Accrued expenses | 60,330 | -123,679 |
| Net cash used in operating activities | -3,171,230 | -6,761,917 |
| Proceeds from issuance of common stock | 375,378 | 459,019 |
| Common stock issuance costs | 17,438 | 18,291 |
| Net cash provided by financing activities | 357,940 | 440,728 |
| Change in cash, cash equivalents and restricted cash | -2,813,290 | -6,321,189 |
| Effect of exchange rate changes on cash | 3,406 | - |
| Cash and cash equivalents at beginning of period | 22,890,055 | - |
| Cash and cash equivalents at end of period | 13,758,982 | - |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)